Glad to be here and thanks for invite @tnewsomdavis.bsky.social great meeting and discussion so far!

@patrickforde.bsky.social on developing ADCs

Press release that HERTHENA-Lung02 has met its primary end point

Could this be an option in (an increasingly crowded) post-Osimertinib field?

But ADCs are challenging in NSCLC. Some explanations 👇

‼️ 1 day until #BTOG25 ‼️
Things to look forward to #6

@patrickforde.bsky.social updating us on ADCs in NSCLC, in Monday morning therapeutics symposium

Recently returned from the USA, now conveniently located at @tcddublin.bsky.social surely solely so he can come to BTOG…

Hopkins crew united!

Great day for lung cancer care!. Addition of just 3 cycles of nivolumab immunotherapy to standard neoadjuvant chemo leads to improved overall survival for surgically resectable lung cancer! Just a press release for now but full data upcoming! #lcsm news.bms.com/news/corpora...

🔥Journal of Clinical Oncology🆙
✅CheckMate 816: Neoadjuvant Nivo + Ipi vs chemo in Resectable NSCLC
👥Drs. Mark Awad, @patrickforde.bsky.social Nicolas Girard,
Jonathan Spicer, Tetsuya Mitsudomi Enriqueta Felip, Mariano Provencio et al.
#LCSM @oncoalert.bsky.social
ascopubs.org/doi/full/10....

Now in @JCO_ASCO led by @DrMarkAwad & @MARIANOPROVENCI exploratory arm neoadj ipi nivo for resectable lung cancer in #CM816 w lots of interesting data! Combo neoadj PD1-CTLA4 blockade without chemo likely not a viable strategy for all comers in NSCLC #lcsm ascopubs.org/doi/10.1200/JC…

Interesting…second line lung cancer trial positive (with caveats), now first line pancreatic cancer. Need to see the paper but TTF is here to stay it seems. Positive Topline Results from Phase 3 PANOVA-3Trial of Tumor Treating Fields for Pancreatic Ca.
www.businesswire.com/news/home/20...

Great summary in @Annals_Oncology of an intensive few days in March 2024 discuss the key issues confronting lung cancer care globally, thanks to Dr. @mayluciemeyer for her excellent leadership on this manuscript! #lcsm @IASLC @myESMO
www.sciencedirect.com/science/arti...

Skyscraper (phase 3 trial of tira plus atezo in PD-L1 high advanced lung cancer) ultimately negative. The rollercoaster is finally back at base, disappointing news and doesn’t bode well for TIGIT as a target. #lcsm
www.gene.com/media/press-...

Excellent presentation by Dr. @VirginiaCalvo6 @gecp_org of the recently published Spanish Lung Cancer Group consensus on management of stage III NSCLC. Neoadjuvant chemo-IO has changed the game for this stage of disease. #lcsm

Seems to be specifically PD1 pathway blockade resistance so some use CTLA4-PD1 combinations (in advanced nsclc)

I would guess it’s a reaction to the drop in US cancer trial accrual post covid & conversely the FDA wanting a minimum percent US accrual to phase 3s but some bright ideas may be best left unexplored

Anyone come across this before? It seems this trial recruitment company cold emails oncologists and offers them cash to refer pts to other centers for specific clinical trials, seems ethically v murky and perhaps legally so as well?

New manuscript in Clinical Cancer Research from Drs. Rosner, Marrone and Smith @hopkinsthoracic analyzing outcomes by KRAS + STK11 mutation status in pts treated with neoadjuvant IO for lung ca #lcsm aacrjournals.org/clincancerre...